As of 2025-05-18, the EV/EBITDA ratio of Vyne Therapeutics Inc (VYNE) is 0.03. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. VYNE's latest enterprise value is -1.37 mil USD. VYNE's TTM EBITDA according to its financial statements is -39.80 mil USD. Dividing these 2 quantities gives us the above VYNE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 6.9x - 9.5x | 7.6x |
| Forward P/E multiples | 10.4x - 16.8x | 13.8x |
| Fair Price | (25.85) - (23.60) | (26.62) |
| Upside | -2218.9% - -2034.5% | -2282.2% |
| Date | EV/EBITDA |
| 2025-04-11 | -0.08 |
| 2025-04-10 | -0.06 |
| 2025-04-09 | -0.12 |
| 2025-04-08 | -0.08 |
| 2025-04-07 | -0.09 |
| 2025-04-04 | -0.10 |
| 2025-04-03 | -0.14 |
| 2025-04-02 | -0.13 |
| 2025-04-01 | -0.08 |
| 2025-03-31 | -0.10 |
| 2025-03-28 | -0.15 |
| 2025-03-27 | -0.18 |
| 2025-03-26 | -0.15 |
| 2025-03-25 | -0.16 |
| 2025-03-24 | -0.17 |
| 2025-03-21 | -0.16 |
| 2025-03-20 | -0.14 |
| 2025-03-19 | -0.18 |
| 2025-03-18 | -0.17 |
| 2025-03-17 | -0.21 |
| 2025-03-14 | -0.21 |
| 2025-03-13 | -0.23 |
| 2025-03-12 | -0.21 |
| 2025-03-11 | -0.22 |
| 2025-03-10 | -0.26 |
| 2025-03-07 | -0.34 |
| 2025-03-06 | -0.39 |
| 2025-03-05 | -0.41 |
| 2025-03-04 | -0.38 |
| 2025-03-03 | -0.40 |
| 2025-02-28 | -0.46 |
| 2025-02-27 | -0.45 |
| 2025-02-26 | -0.47 |
| 2025-02-25 | -0.51 |
| 2025-02-24 | -0.57 |
| 2025-02-21 | -0.55 |
| 2025-02-20 | -0.53 |
| 2025-02-19 | -0.46 |
| 2025-02-18 | -0.45 |
| 2025-02-14 | -0.44 |
| 2025-02-13 | -0.45 |
| 2025-02-12 | -0.46 |
| 2025-02-11 | -0.44 |
| 2025-02-10 | -0.43 |
| 2025-02-07 | -0.42 |
| 2025-02-06 | -0.42 |
| 2025-02-05 | -0.42 |
| 2025-02-04 | -0.40 |
| 2025-02-03 | -0.39 |
| 2025-01-31 | -0.40 |